Business Context and Reporting Period
Company: Rub Music Enterprises, Inc. (post-merger operating as SANUWAVE Health, Inc.)
Filing Date: September 25, 2009
Event: Completion of a Reverse Merger with SANUWAVE, Inc., a medical technology company focused on non-invasive tissue regeneration devices using Pulsed Acoustic Cellular Expression (PACE) technology. The transaction transformed Rub Music from a shell company into an operating entity focused on wound care, orthopedic, and cardiac applications.
Key Financial Metrics
Note: Financial data below reflects SANUWAVE's historical performance prior to the merger, as reported in the filing.
- Revenue (6 months ended June 30, 2009): $0.4 million (down 37% from prior year).
- Net Loss (6 months ended June 30, 2009): $0.8 million.
- Accumulated Deficit (as of June 30, 2009): $33.3 million.
- Cash and Cash Equivalents (as of June 30, 2009): $3.1 million.
- Debt: $3.2 million in notes payable to related parties (Prides Capital and NightWatch Capital) bearing 15% annual interest; $4.0 million in promissory notes to HealthTronics bearing 6% annual interest.
- Share Structure (Post-Merger): 12,509,657 shares outstanding. SANUWAVE stockholders control approximately 88% (11,009,657 shares).
Material Changes vs. Prior Period
- Corporate Structure: Rub Music Enterprises, Inc. ceased being a shell company. SANUWAVE became the accounting acquirer and a wholly-owned subsidiary.
- Management Changes: Cornelius A. Hofman resigned as CEO, President, and CFO. Christopher M. Cashman appointed CEO/President; Barry J. Jenkins appointed CFO.
- Asset Disposition: In June 2009, the company sold its veterinary division (Versatron) for $3.5 million, recording a net gain of $2.5 million. This divestiture allowed a full focus on human medical applications.
- Operational Focus: Shifted entirely to PACE technology for wound healing (dermaPACE), orthopedics, and cardiac conditions. European office closed in April 2009 to reduce costs.
Guidance, Outlook, and Risks
Outlook: Management believes existing cash reserves ($3.1 million) plus $1.8 million in September 2009 securities sales will fund operations through Q1 2010. The company anticipates continued operating losses as it funds clinical trials for dermaPACE (FDA IDE study enrollment ongoing) and prepares for commercialization.
Key Risks:
- Liquidity: Significant uncertainty regarding ability to continue as a going concern without additional financing. No lines of credit exist.
- Regulatory: dermaPACE requires FDA PMA approval (Class III device). Approval is not guaranteed and could be delayed.
- Intellectual Property: Ongoing patent challenges by competitor SwiTech Medical AG in the US and Germany regarding shockwave technology patents.
- Market: Dependence on third-party reimbursement (Medicare/private payers) which is uncertain for new devices.
Investor Verification Checklist
- Verify the status of the FDA Investigational Device Exemption (IDE) clinical trial for dermaPACE in diabetic foot ulcers.
- Confirm the current status of patent litigation with SwiTech Medical AG in the US and Germany.
- Assess the sufficiency of the $3.1 million cash balance against projected R&D and G&A burn rates through Q1 2010.
- Review the terms of the $3.2 million related-party notes (15% interest) and potential dilution upon conversion.
- Validate the timeline for obtaining a Category III CPT code for Medicare reimbursement.